# US 2021/0069302 A1 · Use of pertussis toxin as a therapeutic agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069302 A1
- Document ID: US20210069302A1
- Status: Published application
- Kind: A1
- Application number: 17/083,032
- Filed: 2020-10-28
- Published: 2021-03-11
- Earliest claimed: 2011-06-30
- Assignees: Dignity Health
- Applicants: Dignity Health
- Inventors: Jiong Shi
- Web page: https://patentgrep.com/patent/US20210069302A1

## CPC

- A61K 38/45: Transferases (2)
- A61K 38/164: {from bacteria}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12Y 204/00: Glycosyltransferases (2.4)
- C12Y 204/02031: NAD+-protein-arginine ADP-ribosyltransferase (2.4.2.31)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

The present application relates to the use of pertussis toxin, and its derivatives, analogs, salts and pharmaceutical equivalents. In one embodiment, the invention provides a method of treating or preventing a neurological disease or injury by administering pertussis toxin to the individual.

## Claims

### Claim 1

A method of increasing angiogenesis in a subject having, or suspected of having, multiple sclerosis, the method comprising the steps of:
administering a therapeutically effective dosage of a composition comprising pertussis toxin (PTx) comprising subunits A and B to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition is administered intracerebroventricularly (icv) or intraperitoneally (ip).

### Claim 3 (depends on 1)

The method of claim 1 and further comprising inhibiting migration of T cells into neurologically damaged tissue via administration of the composition.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition is administered to the subject in conjunction with G-protein, chemokine and/or adhesion blocking agents.

### Claim 5 (depends on 1)

The method of claim 1 and further comprising increasing permeability of the blood-brain barrier via administration of the composition.

### Claim 6

A method of reducing demylenation in a subject having, or suspected of having, multiple sclerosis, the method comprising the steps of:
administering a therapeutically effective dosage of a composition comprising pertussis toxin (PTx) comprising subunits A and B to the subject.

### Claim 7 (depends on 6)

The method of claim 6, wherein the composition is administered intracerebroventricularly (icv) or intraperitoneally (ip).

### Claim 8 (depends on 6)

The method of claim 6 and further comprising reducing inflammation in a spinal cord of the subject via administration of the composition.

### Claim 9 (depends on 6)

The method of claim 6, wherein the composition is administered to the subject in conjunction with G-protein, chemokine and/or adhesion blocking agents.
